GLP-1 receptor agonists, including drugs such as Wegovy and Mounjaro, have become increasingly popular for weight management. Alongside their rise, reports of side-effects have also grown, prompting scrutiny from researchers and regulators alike. It is important to separate well-established side-effects from those still under investigation or mainly anecdotal.
Commonly Documented Side-Effects
Digestive issues such as nausea, vomiting, diarrhoea, and constipation are among the most frequently reported side-effects. These are understood to relate to the medication’s mechanism of action, which slows gastric emptying and alters gut-brain signalling. Clinical trials have consistently documented these effects, which are described as very common in patient information leaflets and often diminish over time.
Eye Conditions and Fertility Concerns
Some studies have raised concerns about eye health, including a doubled risk of age-related macular degeneration in people with diabetes using GLP-1 drugs. Additionally, rare cases of non-arteritic anterior ischaemic optic neuropathy, a condition potentially leading to sudden and permanent vision loss, have been reported. These risks are acknowledged by pharmaceutical companies but remain very rare.
Reports of unexpected pregnancies have also emerged, leading to advice that women use effective contraception while on these medications. Theories include possible interference with oral contraceptive efficacy or increased fertility linked to weight loss. However, rigorous research is limited, as pregnancy was generally excluded from clinical trials.
Facial Appearance and Hair Loss
Social media discussions have highlighted changes in facial appearance, such as sagging skin and a sunken look, often referred to as “Ozempic face.” These changes are not specifically linked to any single GLP-1 drug but are recognised by surgeons as a consequence of rapid weight loss from various causes.
Hair loss has recently gained attention following research suggesting a potential association with GLP-1 medications in adults with type 2 diabetes. While patient leaflets for some drugs list hair loss as a common side-effect, experts suggest it may be more related to rapid weight loss and associated metabolic or nutritional changes rather than the medication itself. This is consistent with observations in bariatric surgery patients and crash dieters. The hair loss observed is often a reversible, non-scarring type known as telogen effluvium.
Other Reports and Considerations
Claims such as “Ozempic foot,” describing a bony appearance and foot pain, have been circulated but lack formal documentation in patient information. Podiatrists note that rapid weight loss can reduce fat padding on the feet, potentially causing discomfort.
Given the evolving nature of research in this area, it is essential to approach emerging side-effect reports with caution and rely on verified clinical data where available.
For those interested in peptide science and product literacy, Svelta Labs offers detailed insights and research-use peptides at https://sveltalabs.com.
Research-use disclaimer: This article is intended for educational purposes only and does not provide medical advice or treatment recommendations. Always consult healthcare professionals for personal medical concerns.